Send to

Choose Destination
Oncoimmunology. 2013 Jun 1;2(6):e24462. Epub 2013 May 9.

BRAF-targeted therapy and immune responses to melanoma.

Author information

Immunology in Cancer and Infection Laboratory; Queensland Institute of Medical Research; Herston, QLD Australia ; Department of Pathology; University of Melbourne; Parkville, VIC Australia.


Type I BRAF inhibitors and immunotherapy constitute two new exciting approaches for the treatment of advanced malignant melanoma. We have recently elucidated a role for host C-C chemokine receptor type 2 (CCR2) in the antineoplastic effects of type I BRAF inhibitors in mice, supporting the therapeutic potential of combining BRAF inhibitors with immunotherapy.


BRAF; T cell; checkpoint; immunity; melanoma

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center